Skip to main content
TrendingNews.today
World News
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
As of Mar 26
ScienceChina1 sourcesNeutral

Innovent’s IBI-302 meets phase III endpoints in neovascular AMD

Innovent Biologics Inc.’s efdamrofusp alfa (IBI-302) met the primary endpoint in the phase III Star trial in neovascular age-related macular degeneration (nAMD), and the Suzhou, China-based company will submit an NDA to China’s National Medical Products Administration.

TS
tamra sami
via Bioworld
ShareRead original

Read the full article at Bioworld →

Innovent’s IBI-302 meets phase III endpoints in neovascular AMD

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Bioworld
Bioworld
NewsDataCN

Comments

0 comments
Be respectful and constructive.
Loading comments...
Previous
World Food Prize goes to food safety scientist for preventing millions of cases of foodborne illness
Next
Male Hormones Linked to Aggressive Rare Pediatric Brain Tumor

Related Articles

Extreme global climate outcomes are possible even at 2°C warming, study warnsScience
Extreme global climate outcomes are possible even at 2°C warming, study warns
Phys.org-13h ago-1 sources
Corcept’s Lifyorli wins early FDA approval for ovarian cancerScience
Corcept’s Lifyorli wins early FDA approval for ovarian cancer
Bioworld-13h ago-1 sources
Merck adds Terns’ promising CML drug in $6.7B buyoutScience
Merck adds Terns’ promising CML drug in $6.7B buyout
Bioworld-13h ago-1 sources